Success in recent immunotherapies of cancer, autologous tumor-infiltrating lymphocytes (TIL)/chimeric antigen receptor (CAR) adoptive transfer or re-invigoration of anti-tumor immunity with immune-checkpoint inhibitors, is largely attributable to IFN-γ-dependent anti-tumor effects. This evidence concerns the gene IFNG and cancer.